Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global randomized phase 2 study of STK 012 in combination with pembrolizumab and chemotherapy (PCT)vs. PCT in first-line, PD-L1 negative nonsquamous non-small cell lung cancer (NSCLC).

Next Previous
Trial Profile

A global randomized phase 2 study of STK 012 in combination with pembrolizumab and chemotherapy (PCT)vs. PCT in first-line, PD-L1 negative nonsquamous non-small cell lung cancer (NSCLC).

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics (Primary) ; Pembrolizumab (Primary) ; STK-012 (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms SYNERGY-101

Most Recent Events

  • 25 Nov 2025 New trial record
  • 13 Nov 2025 According to Synthekine media release, first patient has been dosed in this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top